BioSpace News Archive

Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides an opportunity to develop novel treatments for Alzheimer’s disease.

Study Highlights Proprietary Technology for Fetal Fraction Measurement in Non-Invasive Prenatal Testing

Carve out from parent will allow Company to focus on growth and expansion of their business

New technology destroys deadly pathogens and bacteria lurking on hospital surfaces

Vital Therapies, Inc. announced results for the second quarter ended June 30, 2018.

Entered into agreement to acquire Agilis Biotherapeutics

Array BioPharma Inc. will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss those results on Tuesday, August 14, 2018. Ron Squarer, Chief Executive Officer, will lead the call.

Syndax Pharmaceuticals Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018. In addition, the Company provided a clinical and business update. As of June 30, 2018, Syndax had $98.4 million in cash, cash equivalents and short-term investments.

DEXTENZA® NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration